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In cystic fibrosis (CF), airway mucus becomes thick and viscous, and its clearance from the
airways is impaired. The gel-forming mucins undergo an ordered “unpacking/maturation”
process after granular release that requires an optimum postsecretory environment,
including hydration and pH. We hypothesized that this unpacking process is compromised
in the CF lung due to abnormal transepithelial fluid transport that reduces airway surface
hydration and alters ionic composition. Using human tracheobronchial epithelial cells
derived from non-CF and CF donors and mucus samples from human subjects and
domestic pigs, we investigated the process of postsecretory mucin unfolding/maturation,
how these processes are defective in CF airways, and the probable mechanism underlying
defective unfolding. First, we found that mucins released into a normal lung environment
transform from a compact granular form to a linear form. Second, we demonstrated that this
maturation process is defective in the CF airway environment. Finally, we demonstrated that
independent of HCO3
− and pH levels, airway surface dehydration was the major
determinant of this abnormal unfolding process. This defective unfolding/maturation process
after granular release suggests that the CF extracellular environment is ion/water depleted
and likely contributes to abnormal mucus properties in CF airways prior to infection and
inflammation.
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Introduction
The origin of  the thick, sticky airway mucus that characterizes cystic fibrosis (CF) has been the focus 
of  intense study since this disease was first recognized. Much of  the CF disease process is thought to be 
due to a reduction in liquid volume that results from the loss of  CF transmembrane conductance regula-
tor (CFTR) function due to mutations in the CFTR gene (1). Recent work, however, indicates that more 
complicated factors are at play. These factors are secondary to the reduction in volume and are related to 
changes in the physical properties of  the mucus as it becomes concentrated., e.g., alteration of  the postse-
cretory transformation of  polymeric mucins into the linear polymers characteristic of  healthy, transport-
able, mucus. This study focuses on the biochemical maturation of  mucins, specifically MUC5B, following 
their granular release using experimental protocols that are physiologically relevant to the native surfaces 
of  healthy and CF airways.
The CFTR protein normally functions as a cAMP-activated Cl− and HCO3
− channel that is expressed 
in the apical membrane of  a variety of  epithelia, including those of  the sweat glands, pancreas, small intes-
tine, and the tracheobronchial airways of  the lung. In the airways, CFTR is expressed in the apical mem-
branes of  both the ciliated epithelial cells (2) that line the airway surfaces and the serous cells of  the airway 
submucosal glands (3). There are reports of  CFTR being expressed in the secretory membranes of  airway 
goblet cells (4), but this possibility has been questioned (5). In CF disease, the loss of  CFTR-mediated anion 
secretion from airway glands and the surface epithelium, combined with ongoing Na+ absorption through 
ENaC channels in the surface epithelium, is thought to reduce the airway surface liquid (ASL) volume (6).
The polymeric mucins MUC5AC and MUC5B are the major gel-forming macromolecular components 
of  ASL (7). MUC5AC is the product of  goblet cells in the surface epithelium (8, 9), while MUC5B is a 
major product of  the mucous cells of  the submucosal glands (8) and possibly Clara cells in the bronchioles. 
In primary human tracheobronchial epithelial (HTBE) cell cultures, however, both mucins are products 
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of  the surface epithelium, and MUC5B is the dominant mucin in the baseline cultures (5, 10). These large 
oligomeric glycoproteins, especially MUC5B, are vital to the lung’s defenses (11); they provide an initial 
layer of  innate protection for the underlying epithelium against pathological insults, such as inhaled parti-
cles, aerosols, and invading pathogens, which are then removed from the airways via mucociliary transport 
and cough. In the obstructive lung disease CF, the airway mucus becomes thick (concentrated) and viscous, 
and its clearance from the airways is impaired (1). The underlying reasons for the compromise of  mucus 
transportability in this disease state have not been fully defined. Our group has previously demonstrated 
that mucin macromolecules undergo a postsecretory unpackaging process (12) and that mucins are abnor-
mally concentrated in CF lungs (13). The present study was conducted to study in detail the postsecretory 
processing of  these gel-forming mucins, how this process is perturbed in CF, and how qualitative changes 
in mucin maturation might contribute to decreased airway clearance by cough and ciliary transport in CF.
Oligomeric mucins are packaged tightly into secretory granules in the secretory cells. However, the 
intergranular organization of  these extraordinarily large intracellular molecules, the rapidity of  their 
uncoiling following granular release to form transportable mucus gels, and how this process is affected by 
postsecretory extracellular conditions are still unclear. Using freshly secreted salivary MUC5B as a mod-
el, we previously showed in high-resolution electron micrographs that mucin molecules are stored within 
secretory granules with their N- and C-terminal regions arranged in a highly compact granular form and 
that mucins then unpack and expand rapidly following granular release to form linear molecules (12). 
Based on these data, we hypothesized that gel-forming mucins undergo an ordered “unpacking” process 
after granular release that requires an optimal postsecretory environment, including appropriate volume/
hydration and pH conditions, and that this active process is compromised in the CF lung due to abnormal 
airway surface hydration and possibly ionic composition.
In the present study, we tested these hypotheses using three approaches. First, we used primary HTBE 
cells derived from non-CF and CF human donors to test whether mucins undergo a postsecretory unpack-
ing process, as previously proposed (12). Second, we used mucus samples from human CF donors and 
domestic pigs to test whether this important process is defective in the uninfected CF airway milieu, which 
is characterized by alterations in the ionic environment and hydration. Third, to better understand the 
underlying mechanism, we altered the ionic conditions (volume and pH) of  the epithelial surface by inhibit-
ing transepithelial fluid transport to create a CF-like postsecretory environment in an in vitro system.
Results
Postsecretory maturation of  MUC5B in normal and CF cultures. To determine whether MUC5B mucin under-
goes a maturation process after granular release, as previously proposed (12), we used secretions from 
primary human tracheobronchial cell cultures stimulated by the purinergic agonist ATPγS. After agonist 
stimulation, the secretions were collected at 2 minutes, 1 hour, and 4 hours. Figure 1A shows the MUC5B 
distribution in a guanidinium hydrochloride (GuHCl) isokinetic gradient at 2 minutes and at 4 hours. 
Immediately after secretion (2 minutes), approximately 30% of  the MUC5B secreted from non-CF HTBE 
cell cultures resolved as a compact form at the high-density region at the bottom of  the gradient (fractions 
10–12), whereas approximately 20% of  the MUC5B resolved as a linear polymeric form at the top (low-
density) fraction of  the gradient. Over time, there was a progressive shift in this distribution, so that at 4 
hours, approximately 60% of  the mucin resolved at the top of  the gradient as the linearized form (Figure 
1A). The distribution of  MUC5B in the ATPγS-stimulated CF cultures was similar to that of  the 2-minute 
secretion samples, with MUC5B predominantly found in the high-density “compact” region (Figure 1B). 
However, in contrast to the MUC5B profile in the 4-hour secretion samples from non-CF cultures, the CF 
cultures exhibited no progressive shift from the high-density region to the low-density region, suggesting 
that MUC5B remained predominately in a compact form in the CF cultures (Figure 1B) over that period.
To identify the predominant form of  MUC5B in the unstimulated basal secretions that “accumu-
lated” on the non-CF and CF cell surfaces, we analyzed the mucus removed from these cultures prior to 
experimentation on the same gradient. As shown in Figure 1C, the MUC5B recovered from the non-CF 
cultures resolved predominately in the low-density region in the linear form, whereas the majority of  
the MUC5B from the CF HTBE cell cultures was found in the high-density region in the compact form.
Postsecretion unfolding/maturation of  MUC5B in non-CF and CF saliva. To validate and compare our 
findings on MUC5B maturation in airway cell cultures under in vivo conditions, we also evaluated 
mucin processing in non-CF and CF human saliva, which is an accessible source of  MUC5B mucin 
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in both populations. Consistent with our previous observations, 
approximately 70% of  the secreted MUC5B in normal saliva was 
recovered in linear forms in the low-density fractions of  the gradi-
ent (fractions 3–6), while 25% of  the MUC5B was recovered in 
the same middensity region (fractions 7–10) as an intermediate 
semicompact/semilinear form (Figure 2A). Less than 10% of  nor-
mal salivary MUC5B was recovered at the bottom of  the gradient, 
where the compact form is found. In contrast, the MUC5B profile 
of  the saliva from CF patients revealed that approximately 40% of  
the MUC5B population was recovered in a linear form, 40% in the 
semicompact/semilinear and compact forms, and 20% at the bot-
tom of  the gradient in a compact form (Figure 2A). The distribution of  the linear and compact forms 
was significantly different in the CF saliva versus non-CF saliva (P < 0.01; Figure 2B).
Transmission electron microscopy analysis of  the mucin conformation reveals a defective MUC5B unpacking pro-
cess in CF. Physical resolution of  the distinct MUC5B forms in the pools obtained from rate zonal centrifu-
gation was accomplished using transmission electron microscopy. The compact or semiexpanding granular 
mucin form of  MUC5B was the dominant form found at the bottom of  the gradient. In normal saliva, this 
compact form typically appears as glycosylated mucin subunit chains connected around their N- and C-ter-
minal protein nodes, forming 10- to 30-nm spherical core structures (Figure 3E). An analysis of  the same 
fractions from the CF samples indicated that the spherical protein nodes/cores were not as well organized 
and/or processed and were up to 10 times larger (100–300 nm) than normal (Figure 3, C and D). This com-
pact form typically appears as large, irregularly shaped amorphous structures containing an unprocessed 
protein core. We observed these abnormally compact mucin structures in approximately one-third (n = 4) 
of  the CF saliva samples and none of  the normal samples.
Effect of  the absence of  CFTR function on mucin unpacking. To understand the effects of  the inhibition of  
anion secretion on the postsecretory fates of  mucins, we used both non-CF HTBE cell cultures and excised 
domestic pig tracheas. To mimic the defective secretory conditions of  the surface epithelium of  the CF 
airway, HTBE cell cultures were treated with either bumetanide or dimethylamiloride plus acetazolamide 
(DMA+Az) to inhibit transepithelial Cl− and HCO3
− secretion, respectively. Without inhibitors, the apical 
secretions exhibited only 10%–15% of  the MUC5B in the high-density region. In contrast, the inhibition 
of  Cl− and HCO3
− secretion significantly increased the proportion of  MUC5B mucin in the high-density 
compact form region to approximately 30%–40% (P < 0.001; Figure 4, A and B). These apical samples also 
exhibited decreased amounts of  the linear MUC5B form found in the low-density region compared with 
the control (P < 0.01; Figure 4B). The combination of  bumetanide and DMA+Az treatments increased the 
Figure 1. Distribution of the molecular forms of MUC5B following secretion 
from non-CF and CF HTBE cell cultures. After washing the apical surface, 
HTBE cells were stimulated apically with 100 μM ATPγS to induce mucin 
secretion. Apical secretions were collected in PBS at 2 minutes and 240 min-
utes after ATP challenge and immediately added to 4 M GuHCl to preserve 
the molecular forms of mucin. Secretions were then subjected to rate zonal 
centrifugation by a 6–8 M GuHCl gradient to separate the molecular forms 
of MUC5B. (A and B) At 2 minutes, in the ATPγS-stimulated non-CF and CF 
HTBE cell secretions, MUC5B has similar profiles and is found predominantly 
in the high-density “compact” region. (B) However, the MUC5B profile in 
the CF cultures shows no progressive shift from the high-density region to 
the low-density region, as is observed in the non-CF cultures, suggesting 
the MUC5B stays predominately in a compact form in the CF cultures (**P 
= 0.01). (C) The distribution of the molecular forms of MUC5B in “accumu-
lated” secretions in non-CF and CF cultures. Unstimulated basal secretions 
that accumulated on the surface were subjected to the density gradient. 
The MUC5B profiles indicated that the mucins recovered from the accumu-
lated (72 hours) mucus from non-CF cultures resolved predominately in the 
low-density region as the linear form, whereas the majority of the MUC5B 
from CF HTBE cell cultures was found in the same high-density region as the 
compact form (*P = 0.01). SD values are indicated by vertical bars. Unpaired, 
2-tailed t test was used to determine statistical significance.
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mucus concentration significantly (P < 0.0001), from 1.6% (control) to 3.6%, as measured by percentage 
solids (Figure 4C). DMA+Az treatment reduced the pH from 6.8 (control) to 5.6 (Figure 4D; P < 0.0001). 
No pH changes were observed after bumetanide treatment.
Porcine tracheas were also used to investigate the effects of  transepithelial Cl− and HCO3
− secretion 
on the postsecretion unfolding/maturation of  MUC5B. To examine the mechanism underlying Muc5b 
unpacking and the potential reasons for its defective maturation in the CF extracellular milieu, four 
inhibitor pretreatment combinations were applied to the basolateral bath: (a) a combination of  100 μM 
bumetanide and 100 μM DMA; (b) 100 μM bumetanide only; and (c) 100 μM DMA only. One group of  tis-
sues was treated only with buffer with no inhibitors (control). After 45 minutes of  incubation with/without 
the inhibitor(s), acetylcholine (ACh) (100 μM) was added to all tissues to induce mucus secretion. After 2 
hours of  exposure to ACh, the secreted mucus was collected from the cranial end of  the trachea, where it 
pooled as a consequence of  mucociliary transport.
With no inhibitor pretreatment (control), 198 ± 89 μl (mean ± SD) of  mucus was recovered from 
the tracheas after ACh stimulation. These mucus samples contained 600 ± 274 μg/ml (mean ± SD) 
total mucin (Figure 5F). In this control mucus, the majority of  the Muc5b population was recovered 
from the low-density region of  the gradient (fractions 3–5) enriched for linear forms, while only a small 
proportion of  the Muc5b was recovered from the medium-density region (fractions 6–9) enriched for 
the semicompact/semilinear form, and <1%–3% of  the Muc5b was recovered from the high-density 
region of  the gradient (fraction 12) as the compact form (Figure 5A and D). In contrast, the mucus from 
the bumetanide+DMA pretreatment group had a very low total volume, 38 ± 26 μl, with a total mucin 
concentration of  3,200 ± 2,193 μg/ml. Rate zonal centrifugation indicated that the mucus samples from 
the bumetanide+DMA–pretreated tracheas had an abnormal distribution of  Muc5b forms: 10%–25% 
were from the linear form region, 20%–30% were from the semicompact/semilinear form region, and 
approximately 50% were from the same high-density region as the compact form (Figure 5A). The mucus 
samples from the tracheas that were pretreated with only bumetanide also yielded a relatively low vol-
ume of  total mucus, 99 ± 65 μl, with an average total mucin concentration of  1,692 ± 198 μg/ml. The 
profile of  MUC5B on the rate zonal gradient after this pretreatment was similar to the Muc5b distribu-
tion following DMA+bumetanide pretreatment (Figure 5B and E).
To investigate the role of  HCO3
− in the mucin unpacking process, the tracheas were pretreated with 
DMA. This treatment produced 112 ± 65 μl mucus, with an average total mucin concentration of  704 ± 
265 μg/ml (Figure 5C). The density gradient profile of  the Muc5b forms indicated that inhibiting HCO3
− 
Figure 2. Distribution of the molecular forms of salivary MUC5B from non-CF and CF subjects. (A) Approximately 70% 
of the secreted MUC5B population in non-CF saliva was recovered in a linear form in the low-density side of the gradient 
(fractions 3–6), while 25% of the MUC5B was recovered in the middensity region (fractions 7–10) in a semicompact/semi-
linear form. Less than 10% of the MUC5B was recovered in the bottom of the gradient in a compact form. In contrast, the 
MUC5B profile of saliva from CF subjects displayed a different profile, with 40% of the MUC5B population recovered in a 
linear form, while 40% of the MUC5B was found in semicompact/semilinear and compact forms. Approximately 20% of 
MUC5B from CF saliva was recovered in the bottom region in a compact form (*P = 0.01). (B) The distribution of the linear 
and compact forms from normal and CF saliva samples is displayed as a scatter plot (*P = 0.012). Mean and standard 
deviation values are indicated by major and minor horizontal bars respectively. Unpaired, 2-tailed t test was used to deter-
mine statistical significance.
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transport altered the distribution, causing a slight decrease in the linear form and a slight increase in 
the compact region. However, these changes were not significant (Figure 5C). Significant decreases were 
observed in the linear form after bumetanide alone (Figure 5B) and DMA+bumetanide pretreatments 
(P = 0.01). Concomitantly, the proportion of  the compact form increased in the samples pretreated with 
bumetanide alone and with DMA+bumetanide (P = 0.01). In addition, epithelial fluid/mucus secretion 
rates (Jv) and mucin maturation were highly correlated (Figure 6). For example, in low fluid secretion 
rates, e.g., after treatment with bumetanide only (1.98 μl/cm2/h) and DMA+ bumetanide (0.82 μl/
cm2/h), the ratios of  linear mucin to compact mucin (Lm/Cm) were approximately 0.26 and 0.44, respec-
tively, compared with the control (Jv = 6.1 μl/cm2/h and Lm/Cm = 3.9). The mucin in the pig airways 
pretreated with DMA had a slightly increased Jv (7.8 μl/cm2/h), and the Lm/Cm was 1.17 (Figure 6).
Transmission electron microscopy analysis of  the mucus samples from the treated and untreated 
pig tracheas indicated that the Muc5b unpacking process in CF-like airways was defective (Figure 7). 
The mucus from pig tracheas treated with DMA+ bumetanide or bumetanide alone indicated that the 
compact or semiexpanding granular mucin form of  Muc5b was the dominant mucin form found at the 
bottom of  the gradient. As in the saliva experiments (Figure 3), the compact form in nontreated samples 
typically had nodes measuring approximately 10–30 nm (Figure 6E). In the treated samples, however, 
the spherical protein nodes/cores were not as well organized and/or processed and were up to 10 times 
larger (100–300 nm) than normal (Figure 7, C and D).
Discussion
The transportability of  the mucus layer on airway surfaces by the cilia is essential for maintaining normal lung 
health. This mucociliary clearance function of  the airway epithelia is compromised in some diseases, notably 
CF, in which the mucus accumulates in and obstructs the airways, resulting in microbiological colonization. 
Figure 3. Transmission electron micrographs of mucin conformation reveal a defective MUC5B unpacking process in CF. Distribution of the molecular 
forms of salivary MUC5B from a non-CF and CF subject (A) and representative EM images from the top (B) and the bottom (C, D, E) regions. Electron 
microscopy showed that the compact or semiexpanding granular mucin form of MUC5B is the dominant form found at the bottom of the gradient, and 
it typically appears as small numbers of glycosylated mucin subunit chains connected around their N- and C-terminal protein nodes in spherical core 
(10–30 nm) structures (E). In CF samples, however, an analysis of the same fractions indicated that (C and D) the spherical protein nodes/cores are up 
to 10 times larger (100–300 nm) than (E) their normal equivalents. Scale bars: 100 nm.
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The pathogenic mechanism of this mucus obstruction is incompletely understood. The results of  the pres-
ent study provide evidence that an abnormal fluid environment on the airway surfaces corrupts the normal 
unfolding process of  the MUC5B mucin glycoprotein, leading to the secretion of  a dense, compact form of  
MUC5B that likely impairs its clearance by cilia.
The biophysical properties of  the airway mucus layer are strongly influenced by qualitative and quanti-
tative changes in mucins, the dominant macromolecules in airway mucus. Our group has previously shown 
that mucus secretions from CF lungs contain hyperconcentrated mucins that alter the osmotic pressure 
dynamics between the mucus and periciliary liquid layers and play a key a role in disease pathogenesis (13). 
The contribution of  the qualitative properties of  mucins, e.g., their postsecretory unfolding processes, to 
disease progression is not well understood. Here, we provide evidence that qualitative changes in mucins 
in the CF lung might also explain the abnormal mucus properties in CF. These studies highlight the impor-
tance of  postsecretory airway surface conditions for mucin unfolding and the importance of  defective tran-
sepithelial Cl−, HCO3
−, and liquid secretion to the structural transformation of  mucin macromolecules.
In this study, we demonstrated the postsecretory mucin unfolding and maturation abnormalities perti-
nent to CF airway disease and identified the dominant mechanism of  defective unfolding. First, we found 
that mucins are released in compact granular forms and normally transform into linear forms over time. 
Second, we demonstrated that this process is defective in the liquid environment characteristic of  the CF 
airway surface. Finally, we ascertained that, independent from lower HCO3
− and pH levels, airway surface 
dehydration is a major determinant in this unfolding process. It is apparent that this maturation process, in 
which the granular compact mucins transform to the linear form, is critical for having transportable mucus 
in the airways. This unfolding/maturation process, however, may be unfavorable in other mucosal surfaces, 
e.g., the stomach and intestine, in which the mucosal surface needs a tighter barrier that does not require 
mucus transport over the cilia. Therefore, this ordered process is likely to be dynamically controlled by the 
mucosal systems according to their functional requirements.
Following exocytotic secretion in normal airways, mucin molecules rapidly expand in the surface liquid 
of  airways, hydrating them and ultimately forming a mucus gel. This process is essential to producing a 
transportable mucus gel and depends on numerous factors, including mucin chain length, mucin charge 
state, ionic conditions, and the relative hydration state of  the environment (14). There are essentially two 
ways in which mucins might be packaged during synthesis, and Ca2+ plays an important charge-shielding 
role in both cases. According to the Verdugo model (15), mucin oligomers may be packaged as individual, 
randomly tangled strands that would likely fold in regular patterns to form compact structures. More recent 
models described by Kesimer et al. (12), Thornton and colleagues (16), and Hansson and colleagues (17) 
provide evidence that mucins are packaged in a more organized, compact fashion that requires the oligo-
mers to be connected physically in a networked array through their N- and C- terminal regions. Follow-
ing secretion, the oligomeric strands in the Verdugo model (18–20) would simply expand via Donnan 
equilibrium as they hydrate and anneal into mucus, whereas in the Kesimer/Sheehan model, the mucin 
polymers would first need to be freed from the network by ionic exchange and likely proteolytic processing. 
Regardless of  the mechanism involved, this unpacking process is critical for transforming highly compacted 
granular mucins into the linear strands that form the basis of  transportable airway mucus that interacts with 
cilia shafts. It is important to know the route by which secreted mucins mature into mucus, as this has direct 
bearing on the development of  therapies for CF patients.
In this study, we provide evidence of  the postsecretory processing of  MUC5B mucin after granular 
release under controlled conditions. In cultured, well-differentiated airway epithelial cells derived from 
non-CF and CF tissues, we show that MUC5B mucin originates in a highly compacted granular form 
that is processed into a linear form within minutes, with a complete transformation occurring within 4 
hours. Although this observation is predicted by recent studies (12, 16), it was surprising, as earlier stud-
ies had shown that mucus swells within seconds after secretion (20, 21). Mucus swelling due to mucin 
unfolding after granular release depends on a number of  factors, including charge status, hydrophobic-
ity, polymer length, and the ionic conditions of  the extracellular milieu (concentrations of  Na+, Ca+2, 
H+, and HCO3
−, in particular) (14).
Using cell cultures derived from CF lungs and fresh saliva from CF patients, we provide evidence that 
this unpacking process is defective in CF mucus (Figure 1 and Figure 2). The postexocytotic transformation 
of  the compact packaged form of  MUC5B into the linear expanded form is apparently defective in agonist-
induced (Figure 1B) and unstimulated basal secretions (Figure 1C). In CF, the absence of  functional CFTR 
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results in a volume-depleted airway surface, reduced HCO3
− concentration, and a lower pH. The loss of  
CFTR function has at least two consequences: (a) a dehydrated epithelial surface resulting from impaired 
Cl− secretion and (b) an ionically modified epithelial surface liquid caused by impaired HCO3
− secretion. 
Defective HCO3
− secretion could result in reduced pH on the airway surface (22) that could alter the proteo-
lytic environment and/or impair the chelation of  Ca+2 by HCO3
− (23, 24), thereby affecting the dynamics 
of  Na+/Ca+2 exchange. In both cases, the process by which mucin unfolds from a granular to a linear and 
more easily transportable form will be greatly affected.
The intriguing finding of  an unusual, poorly processed, compact form of  MUC5B observed only in 
CF saliva (Figure 3, C and D) also indicates that MUC5B granules are slow to unfold in the CF environ-
ment after release. Electron micrographs of  the mucins secreted from pig tracheas that were pretreated 
with DMA+bumetanide also revealed the presence of  these abnormally organized/unprocessed compact 
mucin forms (Figure 5, C and D). These large, irregularly shaped, poorly processed structures, which have 
an unprocessed protein core that contains mucins, naked protein regions, and other interacting proteins 
(25), render the mucins more compact and possibly more adhesive. Thus, they may bind more strongly to 
epithelial surfaces and the cilia and may interfere with proper ciliary beating dynamics and clearance.
It is important to understand how postsecretory mucin unpacking is compromised under CF postsecre-
tory conditions. To create CF-like conditions in normal HTBE cell cultures, we used the well-established 
inhibitors DMA and bumetanide to inhibit HCO3
− and Cl− secretion, respectively (26). We also removed 
HCO3
− from the buffer and added a carbonic anhydrase inhibitor (Az) to the DMA treatment but not to 
the bumetanide treatment. As summarized in Figure 4, both treatments caused a significant increase in the 
high-density compact form of  MUC5B, suggesting that the unfolding process is greatly affected by these con-
ditions. The bumetanide treatment caused dehydration and increased mucus concentration on the culture 
surfaces, as assessed by measurements of  the percentage of  solids, due to its inhibition of  transepithelial Cl− 
Figure 4. MUC5B distribution after treatments in culture. ATPγS-stimulated culture secretions, after bumetanide (BUM) (10 μM) and 
dimethylamiloride+acetazolamide (DMA+Az; 100 μM) treatment, were subjected to a 6–8 M GuHCl rate zonal centrifugation to determine the macromo-
lecular distribution of MUC5B. (A and B) Compared with no pretreatment control, both treatments led to significantly increased proportions of MUC5B 
mucin, with approximately 30%–40% in the high-density region (**P = 0.002, ***P = 0.0007). The treatment samples also exhibited decreased amounts 
of the MUC5B form found in the light density region, compared with the control (*P = 0.009) (Figure 5D). (C) Both bumetanide and DMA+Az treatments 
increased the mucus concentration significantly (***P = < 0.005), as measured by percentage solids, from 1.6% (control) to 3.6%. (D) DMA+Az treatment 
reduced the pH approximately 1 pH unit from 6.8 (control) to 5.6 (***P = 0.02, ****P = 0.001). No pH changes were observed after bumetanide treatment. 
Bars represent mean ± SD. Statistical significance was determined using 1-way ANOVA.
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secretion. This resulted in a substan-
tial shift in MUC5B from the linear 
to the compact form. DMA+Az 
treatment reduced the pH dramati-
cally, while increasing mucus con-
centration. A role for HCO3
− secre-
tion in this process cannot be ruled 
out. A recent study suggested that 
both pH and Ca++ concentration 
can influence ASL viscosity (27). 
As explained above, these factors 
can substantially affect the unfold-
ing of  mucin from a compact to a 
linear form.
To complement our cell culture 
studies, we also performed experi-
ments using porcine tracheas as a 
model. Previous studies have dem-
onstrated that thick airway mucus 
resembling the mucus observed 
in CF airways can be generated 
in genetically normal domestic 
pig tracheas in vitro by inhibiting 
active Cl− and HCO3
− secretion in 
the presence of  ACh, a stimulant 
of  submucosal gland secretion 
(26, 28). This model mimics the 
CF condition by greatly reducing 
Cl−/HCO3
− and volume through 
the pharmacological inhibition 
of  NKCC and NHE transport-
ers in the basolateral membrane 
of  epithelial secretory cells. In 
the presence of  a mucus secreta-
gogue, such as ACh, mucin secre-
tion from the mucous cells of  the 
submucosal glands is induced, and 
Cl− and HCO3
− secretion is induced 
to drive fluid secretion and gener-
ate well-hydrated mucus. When 
bumetanide and DMA were used 
to inhibit NKCC and NHE, respec-
tively, the resulting secreted mucus 
contained much less salt and H2O, 
resulting in a thick, hyperconcen-
trated, viscous mucus with physical 
properties resembling those of  CF 
mucus (29). It was shown that the 
mucociliary transport rate is dramatically reduced in these conditions (30).
An analysis of  mucin forms after rate zonal centrifugation indicates that this condition has the great-
est effect on mucin unpacking, i.e., it results in the highest percentage of  compact forms and the lowest 
percentage of  linear forms observed across all treatment conditions. Bumetanide-only treatment resulted 
in a similar trend, i.e., significant increases and decreases in the compact and linear forms, respectively. 
As these two conditions had normal levels of  bicarbonate (25 mM) in the buffer, we can surmise that 
Figure 5. Distribution of mucin in CF-like pig tracheas after treatments. Four inhibitor pretreatment combina-
tions were used: (a) 100 μM bumetanide plus 100 μM dimethylamiloride (DMA); (b) 100 μM bumetanide; and 
(c) 100 μM DMA as well as (d) 100 μM ACh, which was added to induce mucus secretion. The control group was 
treated only with 100 μM ACh. (A) In the control mucus, the majority of the MUC5B population was recovered 
on the low-density side of the gradient (top: fractions 3–5) in a linear form, while only a small proportion of the 
MUC5B was recovered in the medium-density region (middle: fractions 6–9) in a semicompact/semilinear form, 
and less than 1%–3% of the MUC5B was recovered in the high-density region of the gradient (bottom: fraction 
12) in a compact form. In contrast, mucus from the bumetanide+DMA pretreatment group had an abnormal dis-
tribution of MUC5B forms: 10%–25% were in a linear form, 20%–30% were in a semicompact/semilinear form, 
and approximately 50% were in a compact form in the high-density region (A). (B) Mucus samples from tracheas 
that were pretreated with only bumetanide also yielded an abnormal Muc5b profile, as did samples pretreated 
with DMA+bumetanide. (C) DMA treatment slightly but not significantly changed the Muc5b profile. Significant 
(P = 0.005) decreases were observed in the linear form after (B) bumetanide alone and (A) DMA+bumetanide 
pretreatments. The proportion of the compact form significantly (P = 0.005) increased after bumetanide alone 
and DMA+bumetanide pretreatments. (D–F) Analysis of the linear and compact forms in these treatments 
compared with the nontreated samples is displayed as a scatter plot. Bars represent mean ± SD (*P = 0.01, **P = 
0.005). Statistical significance was determined using 1-way ANOVA. NT, not treated.
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surface dehydration is an important determinant of  the unpackaging process. 
The greater effect of  bumetanide than DMA alone in inhibiting the maturation 
process is logically related to the fractional effects of  the two anion secretion 
inhibitors, as NKCC-dependent Cl− secretion drives a much greater percent-
age of  liquid secretion in bronchial airways than Na+/H+ exchange–dependent 
HCO3
− secretion (26). This is complementary to the observations made in cell 
culture experiments. Figure 6 illustrates the electron microscopy analysis of  the 
high-density region of  DMA+bumetanide–treated samples, including the com-
pact forms that typically have large, irregularly shaped, amorphous structures, 
which were also observed in human CF saliva.
Regardless of  the underlying cause, the dominance of  unfolded, compact 
mucins in ASL may have adverse consequences for mucus clearance. For instance, 
the exposed/unprocessed protein cores of  the granular/compact form are more 
likely to strongly interact via adhesive interactions with epithelial surfaces, par-
ticularly cilia. The increased interactions with epithelial surfaces and cilia are 
predicted to interfere with effective mucus clearance. Additionally, mucus domi-
nated by compact mucins may possess different biophysical properties that may 
also effect mucociliary clearance. Indeed, mucus released from newborn CF pig 
airways in response to cholinergic stimulation was strongly attached to epithelial 
surfaces and collapsed mucociliary transport (31), and Ballard et al. (32) showed that bumetanide+DMA–
treated mucus, in which the compact mucin is dominant, as described here, was associated with a sig-
nificant reduction in mucociliary transport. Further, in addition to its effect on mucin/mucus biology and 
biophysics, the abnormal maturation process provides information about the local environment into which 
mucins are released and can be used as a surrogate marker of  the hydration status of  the airway surfaces.
In summary, gel-forming mucins in the airways undergo a postsecretory unfolding/maturation process 
after granular release, and this process is defective in the CF environment due to the abnormal airway 
surface milieu resulting from CFTR malfunction. Our data suggest that the airway surface hydration state, 
which is dynamically controlled by the CTFR-related secretion of  both Cl− and HCO3
−, appears to be 
a critical factor in the maturation/unfolding process. Defective maturation produces mucins in a highly 
cross-linked, compact form that is likely to have aberrant biophysical properties that may contribute to the 
defective mucociliary clearance observed in CF airways. Our ongoing studies focus on understanding the 
swelling and other biophysical dynamics associated with the defective maturation process to identify thera-
pies targeted at mucus obstruction in CF.
Methods
Primary human airway epithelial cell cultures. Human tracheobronchial cells from donors were obtained 
in accordance with protocols approved by the IRB of  the University of  North Carolina at Chapel Hill, 
as described previously (33). Cells from non-CF and CF human bronchi were isolated and grown on 
plastic culture dishes in bronchial epithelial cell growth medium. The cells were passaged at 80% con-
fluence, and first/second-passage cells were seeded onto 30-mm Millicell supports at 0.8–1.0 million 
cells per support (Corning). At confluence, the cells were maintained under air-liquid interface (ALI) 
conditions in ALI culture medium, which was changed at the basolateral surface 3 times a week. HTBE 
cells were used for experiments 4–6 weeks after confluence, when the columnar cells were well differen-
tiated into ciliated and goblet cells.
Mucin maturation experiments. HTBE cell cultures derived from non-CF and CF subjects were used to 
study the maturation of  freshly secreted mucins. The cultures were carefully washed with 1 ml PBS, as 
described previously (34), to remove the mucus that accumulated on the luminal surfaces of  cultures dur-
ing the 2–3 days between culture maintenance under ALI conditions. The accumulated mucus wash was 
added to an equal volume of  8 M GuHCl. After a 4-hour washing protocol, the cultures were treated api-
cally with 100 μM ATPγS (30 μl in ALI, pH 7.2 for a 30-mm culture insert, sufficient to form a thin layer 
over the apical surface) to stimulate mucin release (35). The stimulated apical secretions were collected 
in PBS (0.1 ml) at 2, 60, and 240 minutes after ATP challenge (not sequentially — individual cultures 
were used for each time point) and immediately added to 8 M GuHCl to a final concentration of  4 M to 
preserve the molecular forms of  secreted mucins. The apical secretions were used to study the molecular 
Figure 6. Correlation between the rate of liquid volume 
secretion and mucin maturation. Correlation between the 
rate of liquid volume secretion (Jv) and mucin maturation, 
as assessed by the percentage of linear (colored circles) 
and compact forms (colored squares) in control (green), 
dimethylamiloride (DMA) alone (blue), bumetanide alone 
(magenta), and DMA+bumetanide (red) treatments of pig 
bronchi. Horizontal and vertical bars represent ± SD.
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maturation forms of  freshly secreted mucins relative to the time course and the accumulated mucins by 
rate zonal centrifugation, as described below.
Treatments of  HTBE cell cultures. To mimic the behavior of  CF airways in which both Cl− and HCO3
− 
secretions are impaired, the effect of  anion secretion blockers on HTBE cell mucus secretion was investigat-
ed. HTBE cell cultures were washed and pretreated basolaterally for 1 hour with (a) 100 μM bumetanide, 
an inhibitor of  the basolateral Na+-K+-2Cl− cotransporter, in ALI medium with 25 mM HCO3
− and were 
kept in an incubator with 5% CO2 and 95% O2 during the entire experiment, with a set of  untreated cultures 
as controls, or with (b) both DMA (100 μM, a Na+/H+ exchange inhibitor) and Az (100 μM, a carbonic 
anhydrase inhibitor) in HCO3
−-free, HEPES-buffered ALI and were kept in an HCO3
−-free system during 
the entire experiment. Control and pretreated cultures were exposed to ATPγS in test media, as described 
above. Samples were collected after 4 hours. To analyze the molecular forms of  mucin using rate zonal 
centrifugation, apical secretions were collected in PBS and immediately added to 8 M GuHCl to a final 
concentration of  4 M. To measure the percentage of  solids and the pH, apical secretions (~25–30 μl) were 
collected and analyzed immediately.
Rate zonal centrifugation. Samples were subjected to centrifugation on a GuHCl isokinetic density gradi-
ent to study the maturation of  freshly secreted and accumulated mucins in normal and CF cell cultures, as 
described previously (36). Guanidinium chloride (GuCl) gradients (6–8 M) were formed in centrifuge tubes 
using a gradient maker (ISMATEC) connected to a Gilson Minipuls 2 peristaltic pump. Mucin samples (in 
4 M GuCl) were loaded onto the tops of  the gradients and centrifuged in a Beckman Optima L-90K Ultra-
centrifuge (Beckman SW40 rotor) at 285,000 × g for 2.5 hours at 15°C.
Fractions were assayed using slot blots probed with a monoclonal MUC5B antibody (EU-MUC5B) 
that recognizes the peptide sequence RNREQVGKFKMC located in the globular, Cys-rich subdomains 
within the PTS/mucin tandem repeat domains (37) and a polyclonal MUC5B antibody (7). The second-
ary antibodies used were 680-nm goat anti-mouse and 800-nm goat anti-rabbit antibodies (LICOR Biosci-
ences). The signals were detected and analyzed using the Odyssey imaging system (LICOR Biosciences).
Measurements of  the percentage of  solids and the pH of  the HBE secretions. An aliquot (20 μl) of  HBE secre-
tions was weighed on a microbalance (Mettler Toledo UMX2 Microbalance), dried, and weighed again. 
LabView software was used to record the wet and dry weights and the calculation of  percentage of  solids 
(31). A Medical Measurement System (MSS) Orion 11 pH meter and a Greenfield single-use pH catheter 
(MSS) were used to measure the pH of  the apical secretions collected under various treatment conditions. 
Treatment solutions applied to the cultures were used as a control.
Collection and initial processing of  saliva. Unstimulated saliva was collected from 8 healthy volunteers and 
9 CF patients in a clinic. Saliva was collected into a specimen cup on ice. The collected saliva was initially 
centrifuged at 3,000 g for 10 minutes at 4°C to remove cells.
A linear sucrose gradient (10%–30%) in PBS with protease inhibitors (Roche Diagnostics) was created 
using a gradient maker and aliquoted into 12 centrifuge tubes. An aliquot from the supernatant of  the 
saliva was layered onto the gradient. The gradients were then centrifuged for 1 hour at 210,000 g at 4°C 
in an SW-40 swinging bucket rotor. After centrifugation, 1-ml fractions were unloaded from the top and 
subjected to periodic acid–Schiff  and MUC5B immunoblotting.
Collection of  pig airway mucus. Domestic pigs were purchased from the Auburn University Swine 
Research and Education Center (Auburn, Alabama, USA). The pigs (approximately 6–12 kg) were sedated 
with intramuscular telazol (26 mg/kg) and ketamine (18 mg/kg) and euthanized with an overdose of  pen-
tobarbital administered through an ear vein. The tracheas were sectioned immediately below the larynx 
and above the first bronchial branch and removed. The tracheas were then placed in HCO3
−-buffered Krebs 
solution at room temperature and gradually warmed to 37°C over approximately 45 minutes. The Krebs 
solution was constantly bubbled with 95% O2 and 5% CO2 throughout the experiment.
The tracheas were then removed from the bath solution, and the trachealis muscle was resected along 
its length. Each end of  the trachea was carefully tied with a heavy suture onto Lucite cannulas that were 
lightly coated with silicone grease. The cannulas were supported in a rack that held the trachea horizontally 
in space so that the open slot was oriented upward, allowing access to the ventral mucosal surface (for 
a depiction of  this apparatus, see the online supplement for Ballard et al., ref. 30). The rack holding the 
trachea was placed in a weighted polycarbonate box that was partially submerged in a 37°C heated water 
bath. Warm (37°C) Krebs solution was added to the box to bathe the outer surface of  the trachea, but no 
bath solution was allowed to spill into the tracheal lumen. A tempered glass lid was placed on the box to 
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maintain a warm, humidified environment inside the chamber; it was heated to prevent condensation on 
the inner surface of  the lid. The Krebs bath was constantly bubbled with 5% CO2 in O2 gas to keep the pH 
of  the solution close to 7.4.
The tracheas were exposed to the following pretreatments: 100 μM DMA; 100 μM bumetanide; a 
combination DMA+bumetanide solution; and no inhibitor pretreatment, which served as the control. The 
tracheas were exposed to the pretreatment condition for 45 minutes. Then, 100 μM ACh was added to the 
bath to induce mucus secretion. After 2 hours, the secreted mucus was collected with pipettes, transferred 
to Eppendorf  tubes, sealed with parafilm, and refrigerated at 4°C.
The liquid volume secretion rates (Jv = μl.cm
2.h−1) in the control and treatment groups were calculated as 
described in detail elsewhere (38).
Electron microscopic analysis. For the electron microscope analysis, the concentration of  the mucin pool 
was adjusted to approximately 10 μg/ml. The samples were fixed with 0.6% glutaraldehyde for 4 minutes 
at 20°C and mounted on a thin glow-charged carbon-coated grid for 5 minutes. The samples were then 
washed in water-ethanol, as described elsewhere (39). The samples were shadow cast with tungsten and 
observed with a Tecnai 12 electron microscope (FEI) at 40 kV. Images were taken at ×30,000 or ×45,000 
magnification on Kodak SO163 films and scanned with an Imacon 848 film scanner; the contrast was opti-
mized, and panels were arranged using Adobe Photoshop software.
Statistics. Statistical analyses were performed using 1-way ANOVA and standardized 1tailed t tests 
where applicable. A P value of  less than 0.05 was considered significant.
Study approval. Human tracheobronchial cells from donors and the non-CF and CF saliva were obtained 
in accordance with protocols approved by the IRB of  the University of  North Carolina at Chapel Hill. For 
the animal studies, all procedures involving swine were approved by the University of  South Alabama 
Institutional Animal Care and Use Committee and complied with the United States Public Health Service 
Policy on Humane Care and Use of  Laboratory Animals.
Figure 7. Transmission electron microscopy analysis of mucin conformation reveals a defective mucin unpacking 
process in CF-like pig tracheal mucus. A typical distribution of the molecular forms of pig tracheal Muc5b in control and 
CF-like pig trachea (A) and representative EM images from the top (B) and the bottom (C, D and E) regions. (E) As in the 
saliva experiments (Figure 3), the compact form in nontreated samples typically possessed 10- to 30-nm nodes. (C and 
D) In the treated samples, however, spherical protein nodes/cores were not as well organized and/or processed and were 
up to 10 times larger (100–300 nm) than the normal equivalents. Scale bars: 100 nm.
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